BioCryst stock: buy or sell?

BCRX stock price: $3.54 -2.21% At close on June 26th, 2019

Updated on:
June 26th, 2019

1

BioCryst Pharmaceuticals shares eased -2.21% to $3.54 today. Wednesday was the 3rd red session in a row, sliding in full a -4.12%. On Jun 17th BCRX boosted an extraordinary 6.09%.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases.

Should I buy BioCryst stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, BioCryst Pharmaceuticals stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean BCRX will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is BioCryst Pharmaceuticals stock a buy?

Banks and financial institutions publish stock ratings everyday. At Stocks2.com, we gathered 5 ratings published for BCRX stock in the last month.

The general sentiment of these ratings is bullish for BCRX stock, with 3 positive ratings.
Is BCRX a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-5-24Royal Bank of CanadaOutperformSector Perform
2019-5-22Jefferies Financial Groupn/aBuy
2019-4-22Piper Jaffray Companiesn/aBuy
2019-4-2JMP SecuritiesMarket OutperformMarket Outperform
2019-4-2BarclaysEqual WeightEqual Weight

BioCryst stock analysis

Daily outlook

Shares of BioCryst Pharmaceuticals closed today at $3.54 and eased a fateful -2.21%.

BioCryst Pharmaceuticals shares eased -2.21% to $3.54 today. For the last 41 days when BCRX stock price broke down the SMA200d line, it slid $-4.38 per share (-55.30%).

BCRX stock chart (daily)

Weekly outlook

Late May BCRX plunged a hair-raising -120.78% in just one week. After boosting an amazing 8.13% in a week last week, BioCryst closed this week at $3.54 and slipped a terrible -4.07%.

BCRX stock chart (weekly)

BioCryst stock price history

BioCryst stock went public on March 4th, 1994 with a price of $6.251. Since then, BCRX stock declined a -43.40%, with a yearly average of -1.70%.

1: Adjusted price after possible price splits or reverse-splits.

BioCryst stock historical price chart

BCRX stock reached 52-week highs on January at $9.95, and all-time highs 2000-03-09 with a price of 37.25.

BioCryst stock price target is $10.70

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we found 5 price forecasts for BioCryst Pharmaceuticals stock:
BCRX stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-5-24Royal Bank of CanadaDowngrades$16.00$4.50-71.9%
2019-5-22Jefferies Financial GroupLowers Target$13.00$8.00-38.5%
2019-4-22Piper Jaffray CompaniesSet Price Targetn/a$15.00-
2019-4-2JMP SecuritiesRaises Target$16.00$18.0012.5%
2019-4-2BarclaysRaises Target$6.00$8.0033.3%
(in average)$12.80$10.70-16.0%
The price target for BioCryst Pharmaceuticals stock is $10.70, moving in a range between $18.00 and $4.50. In average, analysts' outlook on BCRX price forecast is negative, reducing the forecast by a -16.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

BioCryst let down experts on March when it posted an Earnings per Share (EPS) of $-0.25 when the analysts' forecast was $-0.26.
BCRX earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.19n/a
2017-Q2-n/a-0.21n/a
2017-Q32017-11-07-0.19-0.18n/a
2017-Q42018-02-27-0.14-0.2n/a
2018-Q12018-05-08-0.16-0.26n/a
2018-Q22018-08-07-0.23-0.19n/a
2018-Q32018-11-06-0.25-0.28n/a
2018-Q42019-03-04-0.26-0.25n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In 2018, BioCryst Pharmaceuticals annual turnover plunged a frightening -18.00% to $20.65 M USD from $25.19 marked in 2017. Aligned with this, its income margin (compared to sales) plummed to -490.25%, that is $-101.25 million.

BCRX annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$17 M-$-30.11 M-173.7%-
2014$14 M-21.48%$-45.19 M-332.1%50.08%
2015$48 M254.62%$-43.02 M-89.1%-4.80%
2016$26 M-45.39%$-55.14 M-209.3%28.19%
2017$25 M-4.43%$-65.78 M-261.2%19.29%
2018$21 M-18.00%$-101.25 M-490.3%53.92%

Quarterly financial results

BioCryst Pharmaceuticals posted $2.73 million in sales for 2018-Q4, a 87.69% improvement compared to previous quarter. Reported quarter income marked $-27.43 million with a profit margin of -1,005.20%. Profit margin skyrocketed a 1,030.35% compared to previous quarter when profit margin was -2,035.56%. When comparing turnover to same quarter last year, BioCryst sales marked a dreadful slide and collapsed a -29.85%.
BCRX quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$9 M-$-14.22 M-150.6%-
2017-Q2$3 M-67.16%$-16.89 M-544.8%18.78%
2017-Q3$9 M182.58%$-15.13 M-172.8%-10.40%
2017-Q4$4 M-55.59%$-19.54 M-502.4%29.13%
2018-Q1$4 M2.21%$-25.78 M-648.3%31.90%
2018-Q2$12 M214.24%$-18.45 M-147.6%-28.44%
2018-Q3$1 M-88.36%$-29.60 M-2035.6%60.45%
2018-Q4$3 M87.69%$-27.43 M-1005.2%-7.31%

BioCryst ownership

When you are planning to invest in a stock, it's always worth to overview its ownership structure.

BioCryst shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 1.04% of all shares.

Bearish positions for BCRX stock account 0.00%, no big difference from last month.

For a better context understanding, the following table shows ownership data compared to other related stocks:

BCRXCVMEBSGILDGSK
Market cap$390.5 M$242.3 M$2.4 B$84.7 B$197.5 B
Total shares110.3 M33.7 M51.4 M1,270.0 M4,920.0 M
Float shares60.2 M31.6 M43.1 M1,270.0 M2,440.0 M
  - Institutional holdings (%)93.6%8.7%85.4%82.6%11.0%
  - Insider holdings (%)1.0%5.4%14.9%0.7%0.0%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

BioCryst summary

Wednesday, June 26th, 2019
Open$3.61
Close$3.54
Day range$3.50 - $3.67
Previous close$3.62
Session gain-2.21%
Average true range$0.27
50d mov avg$5.54
100d mov avg$7.00
200d mov avg$7.47
Daily patternlt01a
Weekly pattern lt03a

BioCryst performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared BioCryst Pharmaceuticals against Cel-Sci, Emergent Biosolutions, Gilead Sciences, GlaxoSmithKline, NanoViricides, Repligen and Sarepta Therapeutics in the following table:
Stock3m6m12m
BCRXBioCryst Pharmace...-56.51%-55.08%-38.22%
CVMCel-Sci103.11%148.79%681.52%
EBSEmergent Biosolut...-6.75%-19.73%-6.69%
GILDGilead Sciences3.54%9.83%-2.50%
GSKGlaxoSmithKline-2.74%8.11%4.83%
NNVCNanoViricides-14.81%4.55%-47.73%
RGENRepligen36.21%56.77%71.07%
SRPTSarepta Therapeut...4.17%15.11%-6.07%

BioCryst competitors

One check before trading any stock is to have a look a list of its competitors, in this case for BioCryst Pharmaceuticals. We chose 7 companies as BioCryst Pharmaceuticals competitors as they are in the same industry or have similar market objectives.